Liposome-C-erbB2 antisense oligodoxynucleotides in human ovarian cancer cells.
OBJECTIVE
To explore the effects of liposome-C-erbB2 antisense phosphorothioate oligodeoxynucleotides (S-ODNs) on C-erbB2 proto-oncogene expression and cell proliferation in human ovarian cancer cells.


METHODS
The effects of liposome-C-erbB2 S-ODNs on C-erbB2 protein expression, cell cycle and cell proliferation in human ovarian cancer cells were studied by means of flow cytometry and 3H-thymidine incorporation.


RESULTS
Liposome-C-erbB2 S-ODNs can specifically reduce C-erbB2 protein expression in human ovarian cancer cells, accompanied by a 30% inhibition of cell proliferation. The effectiveness of liposome-C-erbB2 S-ODNs on the expression of C-erbB2 was about 40 times higher than that of C-erbB2 S-ODNs.


CONCLUSIONS
The data suggest that antisense therapy might be a useful method of gene therapy in ovarian cancer. The effectiveness of C-erbB2 S-ODNs could be greatly increased by adsorption of S-ODNs by liposomes.
Shen
M
M
Hospital of Obstetrics and Gynecology, Fu Dan University, Shanghai 200011, China.
Feng
Y
Y
Ge
B
B
Wu
Z
Z
Zhu
M
M
D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D005260:Female; D006801:Humans; D008081:Liposomes; D020319:Oligodeoxyribonucleotides, Antisense / Q000008:administration & dosage*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000090063:Proto-Oncogene Mas; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis / Q000037:antagonists & inhibitors*; D013873:Thionucleotides / Q000008:administration & dosage*; D014407:Tumor Cells, Cultured
D008081:Liposomes; D020319:Oligodeoxyribonucleotides, Antisense; D000090063:Proto-Oncogene Mas; D018719:Erb-b2 Receptor Tyrosine Kinases; D013873:Thionucleotides; C000715470:MAS1 protein, human